Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Terminates Torcetrapib Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Company will investigate whether an increased risk of mortality is a class effect of CETP inhibitors.

You may also be interested in...



Pfizer Turns To Insider Ian Read To See It Into Post-Lipitor Era

The 32-year Pfizer veteran will take over for Jeffrey Kindler in a succession viewed as a surprise by Wall Street.

Pfizer Turns To Insider Ian Read To See It Into Post-Lipitor Era

The 32-year Pfizer veteran will take over for Jeffrey Kindler in a succession viewed as a surprise by Wall Street.

With Genentech Fully Integrated, Roche Lays Out Pipeline

In Roche's first research overview since acquiring Genentech last year, management sought to assure investors that the research engine that developed breakthrough blockbuster medicines like Herceptin and Avastin is still innovating

Related Content

Topics

UsernamePublicRestriction

Register

PS063620

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel